Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.54 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547441 | 1.00 | FOLH1 (0.72) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL6973486 | 0.96 | FOLH1 (0.67) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL1405877 | 0.88 | FOLH1 (0.56) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL10044328 | 0.88 | TDP1 (0.72) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL29928558 | 0.87 | TDP1 (0.75) | FOLH1TDP1PKMCAPN1 | |
| SCHEMBL9807479 | 0.87 | TDP1 (0.77) | FOLH1TDP1PKMCAPN1 | |
| SCHEMBL6972386 | 0.87 | FOLH1 (0.57) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL12809772 | 0.87 | FOLH1 (0.57) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL13497854 | 0.86 | PRSS1 (0.67) | FOLH1TDP1PKMPRSS1PRSS2 | |
| SCHEMBL13497916 | 0.86 | PRSS1 (0.67) | FOLH1TDP1PKMPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445450-B2 | Antithrombotic dual inhibitors comprising a biotin residue | MERCK SHARP & DOHME B.V. (NL) | 2013-05-21 | — | — | US | disclosed |
| US-20120245109-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | MSD OSS B.V. (NL) | 2012-09-27 | — | — | US | disclosed |
| US-20120238512-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | MSD OSS B.V. (NL) | 2012-09-20 | — | — | US | disclosed |
| US-8183228-B2 | Anticoagulant antithrombotic dual inhibitors comprising a biotin label | MSD OSS B.V. Netherlands (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183228-B2 | Anticoagulant antithrombotic dual inhibitors comprising a biotin label | MSD OSS B.V. Netherlands (US) | 2012-05-22 | — | — | US | disclosed |
| US-8168595-B2 | Antithrombotic dual inhibitors comprising a biotin residue | Msd Oss B.V (NL) | 2012-05-01 | — | — | US | disclosed |
| US-8168595-B2 | Antithrombotic dual inhibitors comprising a biotin residue | Msd Oss B.V (NL) | 2012-05-01 | — | — | US | disclosed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| US-20100004186-A1 | Antithrombotic Dual Inhibitors Comprising A Biotin Residue | N.V. ORGANON (NL) | 2010-01-07 | — | — | US | disclosed |
| US-20100004186-A1 | Antithrombotic Dual Inhibitors Comprising A Biotin Residue | N.V. ORGANON (NL) | 2010-01-07 | — | — | US | disclosed |
| WO-2006067173-A2 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | N.V. ORGANON (NL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238512-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | BRS3, SERPINC1, TBXA2R | FOLH1 2963/4885TDP1 4033/4885PKM 4870/4885 |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | FGB, F13B, SERPINC1 | FOLH1 1400/4885TDP1 3436/4885PKM 3835/4885 |
| US-20100004186-A1 | Antithrombotic Dual Inhibitors Comprising A Biotin Residue | SERPINC1, BRS3, TBXA2R | FOLH1 2988/4885TDP1 3824/4885PKM 4870/4885 |
| US-20120245109-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | TBXA2R, MC3R, BRS3 | FOLH1 2786/4885TDP1 3956/4885PKM 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.